TY - JOUR AU - Ryan, Q. AU - Ibrahim, A. AU - Cohen, M. H. AU - Johnson, J. AU - Ko, C. W. AU - Sridhara, R. PY - 2008 DA - 2008// TI - FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic Breast cancer that overexpresses HER-2 JO - Oncologist VL - 13 UR - https://doi.org/10.1634/theoncologist.2008-0816 DO - 10.1634/theoncologist.2008-0816 ID - Ryan2008 ER - TY - JOUR AU - Hortobagyi, G. N. PY - 2005 DA - 2005// TI - Trastuzumab in the treatment of breast cancer JO - N Engl J Med VL - 353 UR - https://doi.org/10.1056/NEJMe058196 DO - 10.1056/NEJMe058196 ID - Hortobagyi2005 ER - TY - JOUR AU - Neves, H. AU - Kwok, H. F. PY - 2015 DA - 2015// TI - Recent advances in the field of anti-cancer immunotherapy JO - BBA Clinical VL - 3 UR - https://doi.org/10.1016/j.bbacli.2015.04.001 DO - 10.1016/j.bbacli.2015.04.001 ID - Neves2015 ER - TY - JOUR AU - Gonzalez-Angulo, A. M. AU - Morales-Vasquez, F. AU - Hortobagyi, G. N. PY - 2007 DA - 2007// TI - Overview of resistance to systemic therapy in patients with breast cancer JO - Adv Exp Med Biol VL - 608 UR - https://doi.org/10.1007/978-0-387-74039-3_1 DO - 10.1007/978-0-387-74039-3_1 ID - Gonzalez-Angulo2007 ER - TY - JOUR AU - Muthuswamy, S. K. PY - 2011 DA - 2011// TI - Trastuzumab resistance: All roads lead to SRC JO - Nat Med VL - 17 UR - https://doi.org/10.1038/nm0411-416 DO - 10.1038/nm0411-416 ID - Muthuswamy2011 ER - TY - JOUR AU - Zhang, S. AU - Huang, W. C. AU - Li, P. AU - Guo, H. AU - Poh, S. B. AU - Brady, S. W. PY - 2011 DA - 2011// TI - Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways JO - Nat Med VL - 17 UR - https://doi.org/10.1038/nm.2309 DO - 10.1038/nm.2309 ID - Zhang2011 ER - TY - JOUR AU - Mayer, E. L. AU - Krop, I. E. PY - 2010 DA - 2010// TI - Advances in targeting Src in the treatment of breast cancer and other solid malignancies JO - Clin Cancer Res VL - 16 UR - https://doi.org/10.1158/1078-0432.CCR-09-1834 DO - 10.1158/1078-0432.CCR-09-1834 ID - Mayer2010 ER - TY - JOUR AU - Tan, M. AU - Li, P. AU - Klos, K. S. AU - Lu, J. AU - Lan, K. H. AU - Nagata, Y. PY - 2005 DA - 2005// TI - ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis JO - Cancer Res VL - 65 UR - https://doi.org/10.1158/0008-5472.CAN-04-2353 DO - 10.1158/0008-5472.CAN-04-2353 ID - Tan2005 ER - TY - JOUR AU - Fan, P. AU - McDaniel, R. E. AU - Kim, H. R. AU - Clagett, D. AU - Haddad, B. AU - Craig Jordan, V. PY - 2012 DA - 2012// TI - Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines JO - Eur J Cancer VL - 48 UR - https://doi.org/10.1016/j.ejca.2012.04.020 DO - 10.1016/j.ejca.2012.04.020 ID - Fan2012 ER - TY - JOUR AU - Peiró, G. AU - Ortiz-Martínez, F. AU - Gallardo, A. AU - Pérez-Balaguer, A. AU - Sánchez-Payá, J. AU - Ponce, J. J. PY - 2014 DA - 2014// TI - Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma JO - Br J Cancer VL - 111 UR - https://doi.org/10.1038/bjc.2014.327 DO - 10.1038/bjc.2014.327 ID - Peiró2014 ER - TY - JOUR AU - Talpaz, M. AU - Shah, N. P. AU - Kantarjian, H. AU - Donato, N. AU - Nicoll, J. AU - Paquette, R. PY - 2006 DA - 2006// TI - Dasatinib in imatinib-resistant Philadelphia chromosome–positive leukemias JO - N Engl J Med VL - 354 UR - https://doi.org/10.1056/NEJMoa055229 DO - 10.1056/NEJMoa055229 ID - Talpaz2006 ER - TY - JOUR AU - Seoane, S. AU - Montero, J. C. AU - Ocaña, A. AU - Pandiella, A. PY - 2010 DA - 2010// TI - Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells JO - J Natl Cancer Inst VL - 102 UR - https://doi.org/10.1093/jnci/djq315 DO - 10.1093/jnci/djq315 ID - Seoane2010 ER - TY - STD TI - Ocana A, Gil-Martin M, Martín M, Rojo F, Antolín S, Guerrero Á, et al. A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study. Oncotarget. 2017. https://doi.org/10.18632/oncotarget.17113. ID - ref13 ER - TY - JOUR AU - Viola-Villegas, N. T. AU - Sevak, K. K. AU - Carlin, S. D. AU - Doran, M. G. AU - Evans, H. W. AU - Bartlett, D. W. PY - 2014 DA - 2014// TI - Noninvasive imaging of PSMA in prostate tumors with89Zr-labeled huJ591 engineered antibody fragments: the faster alternatives JO - Mol Pharm VL - 11 UR - https://doi.org/10.1021/mp500164r DO - 10.1021/mp500164r ID - Viola-Villegas2014 ER - TY - JOUR AU - Janjigian, Y. Y. AU - Viola-Villegas, N. AU - Holland, J. P. AU - Divilov, V. AU - Carlin, S. D. AU - Gomes-DaGama, E. M. PY - 2013 DA - 2013// TI - Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-Trastuzumab PET JO - J Nucl Med VL - 54 UR - https://doi.org/10.2967/jnumed.112.110239 DO - 10.2967/jnumed.112.110239 ID - Janjigian2013 ER - TY - JOUR AU - Lindmo, T. AU - Boven, E. AU - Cuttitta, F. AU - Fedorko, J. AU - Bunn, P. A. PY - 1984 DA - 1984// TI - Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess JO - J Immunol Methods VL - 72 UR - https://doi.org/10.1016/0022-1759(84)90435-6 DO - 10.1016/0022-1759(84)90435-6 ID - Lindmo1984 ER - TY - JOUR AU - Boerner, R. J. AU - Kassel, D. B. AU - Barker, S. C. AU - Ellis, B. AU - DeLacy, P. AU - Knight, W. B. PY - 1996 DA - 1996// TI - Correlation of the phosphorylation states of pp60(c-src) with tyrosine kinase activity: the intramolecular pY530-SH2 complex retains significant activity if Y419 is phosphorylated JO - Biochemistry VL - 35 UR - https://doi.org/10.1021/bi960248u DO - 10.1021/bi960248u ID - Boerner1996 ER - TY - JOUR AU - Belsches-Jablonski, A. P. AU - Biscardi, J. S. AU - Peavy, D. R. AU - D a, T. AU - D a, R. AU - Parsons, S. J. PY - 2001 DA - 2001// TI - Src family kinases and HER2 interactions in human breast cancer cell growth and survival JO - Oncogene VL - 20 UR - https://doi.org/10.1038/sj.onc.1204205 DO - 10.1038/sj.onc.1204205 ID - Belsches-Jablonski2001 ER - TY - JOUR AU - Hudis, C. A. PY - 2007 DA - 2007// TI - Trastuzumab–mechanism of action and use in clinical practice JO - N Engl J Med VL - 357 UR - https://doi.org/10.1056/NEJMra043186 DO - 10.1056/NEJMra043186 ID - Hudis2007 ER - TY - STD TI - Lan KH, Lu CH, Yu D. Mechanisms of trastuzumab resistance and their clinical implications: Annals of the New York Academy of Sciences; 2005. p. 70–5. ID - ref20 ER - TY - JOUR AU - Jin, M. H. AU - Nam, A. -. R. AU - Park, J. E. AU - Bang, J. -. H. AU - Bang, Y. -. J. AU - Oh, D. -. Y. PY - 2017 DA - 2017// TI - Resistance mechanism against trastuzumab in HER2-positive cancer cells and its negation by Src inhibition JO - Mol Cancer Ther VL - 16 UR - https://doi.org/10.1158/1535-7163.MCT-16-0669 DO - 10.1158/1535-7163.MCT-16-0669 ID - Jin2017 ER - TY - JOUR AU - Veach, D. R. AU - Namavari, M. AU - Pillarsetty, N. AU - Santos, E. B. AU - Beresten-Kochetkov, T. AU - Lambek, C. PY - 2007 DA - 2007// TI - Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib JO - J Med Chem VL - 50 UR - https://doi.org/10.1021/jm070342g DO - 10.1021/jm070342g ID - Veach2007 ER - TY - JOUR AU - Dunphy, M. P. S. AU - Zanzonico, P. AU - Veach, D. AU - Somwar, R. AU - Pillarsetty, N. AU - Lewis, J. PY - 2012 DA - 2012// TI - Dosimetry of 18F-labeled tyrosine kinase inhibitor SKI-249380, a dasatinib-tracer for PET imaging JO - Mol Imaging Biol VL - 14 UR - https://doi.org/10.1007/s11307-010-0462-2 DO - 10.1007/s11307-010-0462-2 ID - Dunphy2012 ER - TY - JOUR AU - Holland, J. P. AU - Caldas-Lopes, E. AU - Divilov, V. AU - V a, L. AU - Taldone, T. AU - Zatorska, D. PY - 2010 DA - 2010// TI - Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab JO - PLoS One VL - 5 UR - https://doi.org/10.1371/journal.pone.0008859 DO - 10.1371/journal.pone.0008859 ID - Holland2010 ER - TY - JOUR AU - Massicano, A. d. r. i. a. n. a. V. F. AU - Marquez-Nostra, B. e. r. n. a. d. e. t. t. e. V. AU - Lapi, S. u. z. a. n. n. e. E. PY - 2018 DA - 2018// TI - Targeting HER2 in Nuclear Medicine for Imaging and Therapy JO - Molecular Imaging VL - 17 UR - https://doi.org/10.1177/1536012117745386 DO - 10.1177/1536012117745386 ID - Massicano2018 ER - TY - JOUR AU - Dong, H. AU - Ma, L. AU - Gan, J. AU - Lin, W. AU - Chen, C. AU - Yao, Z. PY - 2017 DA - 2017// TI - PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2 JO - Oncogene VL - 36 UR - https://doi.org/10.1038/onc.2016.213 DO - 10.1038/onc.2016.213 ID - Dong2017 ER -